Axsome Therapeutics (AXSM) Return on Equity (2016 - 2026)

Axsome Therapeutics' Return on Equity history runs 11 years deep, the most recent figure standing at 0.03% for Q1 2026.

• In Q1 2026, Return on Equity rose 2.0% year-over-year to 0.03%; the TTM figure through Mar 2026 stood at 0.03% (up 2.0% YoY), while the FY2025 annual figure was 0.03%, changed 0.0% from the prior year.
• Return on Equity came in at 0.03% for Q1 2026 at Axsome Therapeutics, down from 0.02% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.01% in Q3 2023 to a low of 0.1% in Q2 2022.
• A 5-year average of 0.03% and a median of 0.02% in 2024 frame the typical range for Return on Equity.
• Across the five-year window, Return on Equity slipped 9 bps in 2022 and advanced 9 bps in 2023, its largest moves.
• Axsome Therapeutics' Return on Equity stood at 0.01% in 2022, then grew by 26 bps to 0.01% in 2023, then tumbled by 269 bps to 0.04% in 2024, then surged by 41 bps to 0.02% in 2025, then declined by 17 bps to 0.03% in 2026.
• According to Business Quant data, Return on Equity over the past three periods registered 0.03%, 0.02%, and 0.03% for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison